SAN DIEGO, Nov. 03, 2016 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that six abstracts highlighting the Company's programs, including an oral presentation on its natural killer (NK) cell product candidate FATE-NK100 as well as multiple poster presentations on its off-the-shelf cancer immunotherapy pipeline, have been accepted for presentation at the 58 th American Society of Hematology (ASH) Annual Meeting and Exposition. The meeting will be held December 3-6, 2016 in San Diego. ASH Presentations on Fate Therapeutics' Programs FATE-NK100: TITLE: Development and Scale-up of a Novel GMP Method for Enrichment and Expansion of Terminally Differentiated Adaptive Natural Killer Cells (FATE-NK100) with Enhanced Anti-Tumor Function Frank Cichocki Publication Number: 1225 Session Name: 711. Cell Collection and Processing: Immunotherapy, Immunomodulation, and Immune Reconstitution Date and Time: Monday, December 5, 2016, 6:15 PM Room: San Diego Convention Center, Room 30 Off-the-Shelf Cancer Immunotherapy: TITLE: Off-the-Shelf Natural Killer Cell Immunotherapy for Enhanced Antibody Directed Cellular CytotoxicityRyan Bjordahl Publication Number: 3363 Session Name: 703. Adoptive Immunotherapy: Poster II Date and Time: Sunday, December 4, 2016, 6:00 PM - 8:00 PM Location: San Diego Convention Center, Hall GH TITLE: Genetically Enhanced Pluripotent Stem Cell-Derived T Lymphocytes for Off-the-Shelf Cellular Immunotherapy Raedun Clarke Publication Number: 2164 Session Name: 703. Adoptive Immunotherapy: Poster I Date and Time: Saturday, December 3, 2016, 5:30 PM - 7:30 PM Location: San Diego Convention Center, Hall GH TITLE: Genetic Engineering of Pluripotent Cells for the Continuous Derivation of Off-the-Shelf Effector Lymphocytes with Enhanced Therapeutic Persistence by Overcoming the Host Histocompatibility Barrier Raedun Clarke Publication Number: 2165 Session Name: 703. Adoptive Immunotherapy: Poster I Date and Time: Saturday, December 3, 2016, 5:30 PM - 7:30 PM Location: San Diego Convention Center, Hall GH Collaboration with Juno Therapeutics: TITLE: Identification of Small Molecule Modulators to Enhance the Therapeutic Properties of Chimeric Antigen Receptor T CellsJonathan Rosen Publication Number: 4712 Session Name: 802. Chemical Biology and Experimental Therapeutics: Poster III Date and Time: Monday, December 5, 2016, 6:00 PM - 8:00 PM Location: San Diego Convention Center, Hall GH ProTmune™: TITLE: Economic Burden of Acute Graft-Versus-Host Disease (GvHD) Following Allogeneic Hematopoietic Cell Transplant (HCT) for Hematologic MalignanciesWalter Grubb Publication Number: 1187 Session Name: 902. Health Services Research—Malignant Conditions: At the Corner of Cost and Efficacy Date and Time: Monday, December 5, 2016, 5:30 PM Room: San Diego Convention Center, Room 28 A-D About Fate Therapeutics, Inc.Fate Therapeutics is a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders. The Company's hematopoietic cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf product candidates derived from engineered induced pluripotent cells, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients undergoing hematopoietic cell transplantation and to promote immune tolerance in patients with autoimmune disease. Its adoptive cell therapy programs are based on the Company's novel ex vivo cell programming approach, which it applies to modulate the therapeutic function and direct the fate of immune cells. Fate Therapeutics is headquartered in San Diego, CA. For more information, please visit www.fatetherapeutics.com.
Contact:Christina TartagliaStern Investor Relations, Inc.email@example.com